BOLT
Bolt Biotherapeutics, Inc.
Price Chart
Latest Quote
$3.99
-0.22 (-5.23%)
Current Price
| Previous Close | $4.21 |
| Open | $4.30 |
| Day High | $4.59 |
| Day Low | $3.99 |
| Volume | 67,812 |
Stock Information
| Shares Outstanding | 1.92M |
| Total Debt | $22.31M |
| Cash Equivalents | $22.89M |
| Revenue | $6.50M |
| Net Income | $-29.58M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.67M |
| EPS (TTM) | $-16.28 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.08M |
| Sales | $6.50M |
| Income | $-29.58M |
| Book/sh | $10.32 |
| Cash/sh | $11.91 |
| Employees | 23 |
Financial Ratios
| Quick Ratio | 3.12 |
| Current Ratio | 3.51 |
| Debt/Eq | 112.54 |
Returns & Margins
| ROA | -28.12% |
| ROE | -88.79% |
| Gross Margin | -268.15% |
| Operating Margin | -29234.62% |
Ownership
| Insider Ownership | 7.11% |
| Institutional Ownership | 28.86% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.02 |
| P/S | 1.18 |
| P/B | 0.39 |
Analyst Data
| Recommendation | none |
| Target Price | $41.00 |
Technical Indicators
| SMA20 | $4.75 |
| SMA50 | $4.78 |
| SMA200 | $5.14 |
| RSI | 26.67 |
| ATR | 0.4089 |
| Shares Float | 1.77M |
| Short Float | 0.68% |
| Short Ratio | 0.49 |
| Volatility | 1.13 |
| Rel Volume | 2.26 |
Performance History
| Week | -16.35% |
| Month | -15.47% |
| Quarter | -12.11% |
| 6 Months | -26.79% |
| YTD | -31.09% |
| Year | -29.26% |
| 3 Years | -87.61% |
| 5 Years | -98.78% |
| 10 Years | -99.38% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $3.99 | 68,100 |
| 2026-06-17 | $4.21 | 113,800 |
| 2026-06-16 | $4.31 | 12,700 |
| 2026-06-15 | $4.59 | 12,600 |
| 2026-06-12 | $4.56 | 52,500 |
| 2026-06-11 | $4.77 | 102,200 |
| 2026-06-10 | $4.43 | 11,500 |
| 2026-06-09 | $4.62 | 4,800 |
| 2026-06-08 | $4.72 | 6,700 |
| 2026-06-05 | $4.56 | 11,000 |
| 2026-06-04 | $4.76 | 15,700 |
| 2026-06-03 | $4.63 | 24,100 |
| 2026-06-02 | $5.11 | 12,700 |
| 2026-06-01 | $5.31 | 22,000 |
| 2026-05-29 | $5.25 | 21,500 |
| 2026-05-28 | $5.30 | 11,300 |
| 2026-05-27 | $5.28 | 34,400 |
| 2026-05-26 | $5.13 | 9,400 |
| 2026-05-22 | $4.95 | 22,100 |
| 2026-05-21 | $4.59 | 33,200 |
| 2026-05-20 | $4.61 | 92,600 |
| 2026-05-19 | $4.72 | 16,200 |
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
đ° Latest News
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-12T21:40:03Z
Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates
Zacks âĸ 2026-03-12T21:45:02Z
Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-12T20:51:56ZBolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates
Zacks âĸ 2025-11-12T22:25:02Z
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-12T21:21:55ZBolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
Zacks âĸ 2025-11-04T15:00:03Z
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires âĸ 2025-10-02T19:58:43ZWashington Shutdown Continues as US Equity Futures Trade Mixed Ahead of Opening Bell
MT Newswires âĸ 2025-10-02T13:20:37ZBolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates
Zacks âĸ 2025-08-14T21:25:01Z
Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-14T20:24:06Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $7,695,000 | $7,690,000 | $7,876,000 | $5,729,000 |
| Operating Revenue | $7,695,000 | $7,690,000 | $7,876,000 | $5,729,000 |
| Expenses | ||||
| Total Expenses | $42,328,000 | $75,926,000 | $84,072,000 | $96,050,000 |
| Other Income Expense | $-1,239,000 | $-137,000 | - | - |
| Other Non Operating Income Expenses | $241,000 | $4,675,000 | - | - |
| Net Non Operating Interest Income Expense | $2,496,000 | $5,255,000 | $6,999,000 | $2,223,000 |
| Operating Expense | $42,328,000 | $75,926,000 | $84,072,000 | $96,050,000 |
| General And Administrative Expense | $13,795,000 | $18,457,000 | $22,530,000 | $22,927,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Net Interest Income | $2,496,000 | $5,255,000 | $6,999,000 | $2,223,000 |
| Interest Income | $2,496,000 | $5,255,000 | $6,999,000 | $2,223,000 |
| Normalized Income | $-31,896,000 | $-58,306,000 | $-69,197,000 | $-88,098,000 |
| Net Income From Continuing And Discontinued Operation | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Total Operating Income As Reported | $-36,113,000 | $-73,048,000 | $-76,196,000 | $-90,321,000 |
| Net Income Common Stockholders | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Net Income | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Net Income Including Noncontrolling Interests | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Net Income Continuous Operations | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Pretax Income | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Special Income Charges | $-1,480,000 | $-4,812,000 | $0 | - |
| Interest Income Non Operating | $2,496,000 | $5,255,000 | $6,999,000 | $2,223,000 |
| Operating Income | $-34,633,000 | $-68,236,000 | $-76,196,000 | $-90,321,000 |
| Per Share | ||||
| Diluted EPS | $-17.85 | $-33.00 | $-36.60 | $-47.20 |
| Basic EPS | $-17.85 | $-33.00 | $-36.60 | $-47.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-31,862,000 | $-61,643,000 | $-74,342,000 | $-88,655,000 |
| Total Unusual Items | $-1,480,000 | $-4,812,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $-1,480,000 | $-4,812,000 | $0 | - |
| Reconciled Depreciation | $1,291,000 | $1,781,000 | $1,854,000 | $1,666,000 |
| EBITDA (Bullshit earnings) | $-33,342,000 | $-66,455,000 | $-74,342,000 | $-88,655,000 |
| EBIT | $-34,633,000 | $-68,236,000 | $-76,196,000 | $-90,321,000 |
| Diluted Average Shares | $1,869,924 | $1,909,196 | $1,890,599 | $1,867,921 |
| Basic Average Shares | $1,869,924 | $1,909,196 | $1,890,599 | $1,867,921 |
| Diluted NI Availto Com Stockholders | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Impairment Of Capital Assets | $0 | $1,469,000 | $0 | - |
| Restructuring And Mergern Acquisition | $1,480,000 | $3,343,000 | $0 | - |
| Research And Development | $28,533,000 | $57,469,000 | $61,542,000 | $73,123,000 |
| Selling General And Administration | $13,795,000 | $18,457,000 | $22,530,000 | $22,927,000 |
| Other Gand A | $13,795,000 | $18,457,000 | $22,530,000 | $22,927,000 |
| Gain On Sale Of Security | - | - | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Total Assets | $56,748,000 | $99,632,000 | $159,784,000 | $227,807,000 |
| Total Non Current Assets | $26,488,000 | $48,818,000 | $54,076,000 | $55,061,000 |
| Other Non Current Assets | $1,676,000 | $1,043,000 | $3,586,000 | $2,593,000 |
| Investmentin Financial Assets | $4,337,000 | $22,880,000 | $26,413,000 | $23,943,000 |
| Current Assets | $30,260,000 | $50,814,000 | $105,708,000 | $172,746,000 |
| Other Current Assets | $653,000 | $509,000 | $1,086,000 | $3,858,000 |
| Restricted Cash | $200,000 | $784,000 | $0 | - |
| Prepaid Assets | $929,000 | $1,033,000 | $906,000 | - |
| Receivables | $973,000 | $1,165,000 | $1,527,000 | - |
| Other Receivables | $973,000 | $1,165,000 | $1,527,000 | - |
| Cash Cash Equivalents And Short Term Investments | $27,505,000 | $47,323,000 | $102,189,000 | $168,888,000 |
| Cash And Cash Equivalents | $11,703,000 | $7,205,000 | $10,810,000 | $9,244,000 |
| Non Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $22,958,000 | $25,209,000 | $20,219,000 | $22,611,000 |
| Long Term Debt And Capital Lease Obligation | $20,132,000 | $22,958,000 | $17,437,000 | $20,220,000 |
| Current Debt And Capital Lease Obligation | $2,826,000 | $2,251,000 | $2,782,000 | $2,391,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $30,243,000 | $42,434,000 | $47,043,000 | $56,301,000 |
| Total Non Current Liabilities Net Minority Interest | $21,808,000 | $26,578,000 | $26,587,000 | $33,183,000 |
| Other Non Current Liabilities | $132,000 | - | $43,000 | $42,000 |
| Non Current Deferred Liabilities | $1,544,000 | $3,620,000 | $9,107,000 | $12,921,000 |
| Current Liabilities | $8,435,000 | $15,856,000 | $20,456,000 | $23,118,000 |
| Current Deferred Liabilities | $449,000 | $3,015,000 | $2,201,000 | $1,993,000 |
| Payables And Accrued Expenses | $3,518,000 | $6,387,000 | $9,653,000 | $13,930,000 |
| Payables | $1,443,000 | $1,507,000 | $2,987,000 | $3,594,000 |
| Accounts Payable | $1,443,000 | $1,507,000 | $2,987,000 | $3,594,000 |
| Equity | ||||
| Common Stock Equity | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Total Equity Gross Minority Interest | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Stockholders Equity | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Gains Losses Not Affecting Retained Earnings | $-21,000 | $97,000 | $37,000 | $-919,000 |
| Other Equity Adjustments | $-21,000 | $97,000 | $37,000 | $-919,000 |
| Retained Earnings | $-460,779,000 | $-427,403,000 | $-364,285,000 | $-295,088,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $1,920,566 | $1,916,984 | $1,905,730 | $1,889,895 |
| Share Issued | $1,920,566 | $1,916,984 | $1,905,730 | $1,889,895 |
| Tangible Book Value | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Invested Capital | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Working Capital | $21,825,000 | $34,958,000 | $85,252,000 | $149,628,000 |
| Capital Lease Obligations | $22,958,000 | $25,209,000 | $20,219,000 | $22,611,000 |
| Total Capitalization | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Additional Paid In Capital | $487,305,000 | $484,504,000 | $476,989,000 | $467,513,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $1,544,000 | $3,620,000 | $9,107,000 | $12,921,000 |
| Long Term Capital Lease Obligation | $20,132,000 | $22,958,000 | $17,437,000 | $20,220,000 |
| Current Deferred Revenue | $449,000 | $3,015,000 | $2,201,000 | $1,993,000 |
| Current Capital Lease Obligation | $2,826,000 | $2,251,000 | $2,782,000 | $2,391,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,642,000 | $4,203,000 | $5,820,000 | $4,804,000 |
| Current Accrued Expenses | $2,075,000 | $4,880,000 | $6,666,000 | $10,336,000 |
| Investments And Advances | $4,337,000 | $22,880,000 | $26,413,000 | $23,943,000 |
| Available For Sale Securities | $4,337,000 | $22,880,000 | $26,413,000 | $23,943,000 |
| Net PPE | $20,475,000 | $24,895,000 | $24,077,000 | $28,525,000 |
| Accumulated Depreciation | $-7,387,000 | $-7,278,000 | $-5,752,000 | $-3,915,000 |
| Gross PPE | $27,862,000 | $32,173,000 | $29,829,000 | $32,440,000 |
| Leases | $358,000 | $286,000 | $285,000 | $272,000 |
| Other Properties | $27,118,000 | $31,501,000 | $29,158,000 | $31,810,000 |
| Machinery Furniture Equipment | $386,000 | $386,000 | $386,000 | $358,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $15,802,000 | $40,118,000 | $91,379,000 | $159,644,000 |
| Treasury Shares Number | - | - | $0 | - |
| Preferred Stock | - | - | $0 | $0 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-39,922,000 | $-61,330,000 | $-69,731,000 | $-78,457,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-39,850,000 | $-61,289,000 | $-69,525,000 | $-76,504,000 |
| Cash Flow From Continuing Operating Activities | $-39,850,000 | $-61,289,000 | $-69,525,000 | $-76,504,000 |
| Operating Gains Losses | $-288,000 | $-70,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-72,000 | $-41,000 | $-206,000 | $-1,953,000 |
| Investing Cash Flow | $44,302,000 | $57,576,000 | $71,038,000 | $57,862,000 |
| Cash Flow From Continuing Investing Activities | $44,302,000 | $57,576,000 | $71,038,000 | $57,862,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $19,000 | $108,000 | $253,000 | $503,000 |
| Financing Cash Flow | $19,000 | $108,000 | $253,000 | $503,000 |
| Cash Flow From Continuing Financing Activities | $19,000 | $108,000 | $253,000 | $503,000 |
| Net Common Stock Issuance | $19,000 | $108,000 | $253,000 | $503,000 |
| Common Stock Issuance | $19,000 | $108,000 | $253,000 | $503,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $13,441,000 | $8,970,000 | $12,575,000 | $10,809,000 |
| Beginning Cash Position | $8,970,000 | $12,575,000 | $10,809,000 | $28,948,000 |
| Changes In Cash | $4,471,000 | $-3,605,000 | $1,766,000 | $-18,139,000 |
| Net Investment Purchase And Sale | $43,411,000 | $57,469,000 | $71,244,000 | $59,815,000 |
| Sale Of Investment | $72,427,000 | $146,324,000 | $236,232,000 | $240,519,000 |
| Purchase Of Investment | $-29,016,000 | $-88,855,000 | $-164,988,000 | $-180,704,000 |
| Net PPE Purchase And Sale | $891,000 | $107,000 | $-206,000 | $-1,953,000 |
| Sale Of PPE | $963,000 | $148,000 | $0 | - |
| Purchase Of PPE | $-72,000 | $-41,000 | $-206,000 | $-1,953,000 |
| Change In Working Capital | $-12,115,000 | $-8,440,000 | $-9,864,000 | $-3,057,000 |
| Change In Other Working Capital | $-4,642,000 | $-4,673,000 | $-3,606,000 | $-2,162,000 |
| Change In Other Current Liabilities | $-2,119,000 | $-1,455,000 | $-2,391,000 | $-2,760,000 |
| Change In Payables And Accrued Expense | $-5,430,000 | $-4,883,000 | $-3,413,000 | $2,768,000 |
| Change In Prepaid Assets | $76,000 | $2,571,000 | $-454,000 | $-903,000 |
| Other Non Cash Items | $2,526,000 | $2,297,000 | $2,952,000 | $3,225,000 |
| Stock Based Compensation | $2,782,000 | $7,407,000 | $9,223,000 | $9,576,000 |
| Asset Impairment Charge | $0 | $1,469,000 | $0 | - |
| Amortization Of Securities | $-670,000 | $-2,615,000 | $-4,493,000 | $184,000 |
| Depreciation Amortization Depletion | $1,291,000 | $1,781,000 | $1,854,000 | $1,666,000 |
| Depreciation And Amortization | $1,291,000 | $1,781,000 | $1,854,000 | $1,666,000 |
| Gain Loss On Sale Of PPE | $-288,000 | $-70,000 | $0 | $0 |
| Net Income From Continuing Operations | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Unrealized Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-19